These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11392625)

  • 1. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine.
    Hills CJ; Winter SA; Balfour JA
    Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
    Appell RA
    Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine once-daily in treatment of the overactive bladder.
    Peters KM; Huang RR
    Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
    Sussman D; Garely A
    Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic receptor antagonists in the treatment of overactive bladder.
    Chapple CR
    Urology; 2000 May; 55(5A Suppl):33-46; discussion 50. PubMed ID: 10767450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
    Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.
    Appell RA
    Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
    Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.